CMPS

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.12
Percentage change -3.55	%

Peers: MNMD ATAI CYBN GHRS RLMD AXSM MNOV XENE PRTA TVRD

| Held by: ARKG IBB PSIL SBIO GWX BBC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.95	Insider Own	9.34%	Shs Outstand	92.85M	Perf Week	22.56%
Market Cap	302.69M	Forward P/E	-	EPS next Y	-1.49	Insider Trans	0.00%	Shs Float	84.17M	Perf Month	-28.98%
Enterprise Value	74.23M	PEG	-	EPS next Q	-0.43	Inst Own	46.69%	Short Float	6.29%	Perf Quarter	5.50%
Income	-137.90M	P/S	-	EPS this Y	32.95%	Inst Trans	126.56%	Short Ratio	2.30	Perf Half Y	-13.07%
Sales	0.00M	P/B	1.55	EPS next Y	3.20%	ROA	-43.91%	Short Interest	5.29M	Perf YTD	-13.76%
Book/sh	2.11	P/C	1.16	EPS next 5Y	16.96%	ROE	-60.67%	52W High	8.54 -61.81%	Perf Year	-45.21%
Cash/sh	2.81	P/FCF	-	EPS past 3/5Y	-8.64% -	ROIC	-63.47%	52W Low	2.25 44.89%	Perf 3Y	-68.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.31% 10.74%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.52%	Oper. Margin	-	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.65	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	10.18	EPS Q/Q	63.28%	SMA20	-14.75%	Beta	2.12	Target Price	15.78
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	-18.05%	Rel Volume	0.59	Prev Close	3.38
Employees	166	LT Debt/Eq	0.11	Earnings	May 08 BMO	SMA200	-25.51%	Avg Volume	2.30M	Price	3.26
IPO	Sep 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	48.62% -	Trades		Volume	1,368,745	Change	-3.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-25	Downgrade	Evercore ISI	Outperform → In-line	$11 → $6
Feb-27-25	Initiated	Stifel	Buy	$11
Jul-23-24	Initiated	RBC Capital Mkts	Outperform	$23
Apr-01-24	Initiated	Morgan Stanley	Overweight	$30
Dec-12-23	Initiated	Deutsche Bank	Buy	$16
Nov-21-22	Resumed	Berenberg	Buy	$33
Nov-01-22	Initiated	Loop Capital	Buy	$34
Oct-29-21	Initiated	Oppenheimer	Outperform	$50
Jul-13-21	Initiated	Citigroup	Buy	$67
Jun-28-21	Initiated	Maxim Group	Buy	$70
May-11-21	Initiated	Cantor Fitzgerald	Overweight	$71
Apr-01-21	Initiated	ROTH Capital	Buy	$88
Oct-14-20	Initiated	H.C. Wainwright	Buy	$65
Oct-13-20	Initiated	Evercore ISI	Outperform
Oct-13-20	Initiated	Cowen	Outperform
Oct-13-20	Initiated	Canaccord Genuity	Buy	$80
Oct-13-20	Initiated	Berenberg	Buy	$50

Show Previous Ratings

Jun-29-25 06:01PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:00AM	This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip? (Barchart)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-24-25 07:10AM	Compass stock slips despite psilocybin trial hitting target (Clinical Trials Arena) +7.66%
Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -49.24%
07:30AM	Loading…
07:30AM	Compass big psychedelic study doesnt impress investors (BioPharma Dive)
06:30AM	Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-18-25 08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile) +7.14%
May-14-25 12:00PM	COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know (Zacks)
06:30AM	Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
03:12AM	Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ... (GuruFocus.com)
May-08-25 06:30AM	Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights (Business Wire)
06:00PM	Loading…
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:34PM	COMPASS Pathways ADS Q1 2025 Earnings Preview (Seeking Alpha)
Apr-29-25 06:30AM	Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities (Business Wire)
Apr-28-25 06:30AM	Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 (Business Wire)
Apr-27-25 03:31PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-25-25 06:13PM	Why Compass Pathways Stock Was a Double-Digit Winner This Week (Motley Fool)
11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-22-25 06:00AM	Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire) +5.62%
Mar-28-25 05:01PM	This Is a Test From GlobeNewswire (GlobeNewswire)
Mar-26-25 06:30AM	Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-20-25 11:15AM	Lazard International Strategic Equity Portfolio Q4 2024 Commentary (SeekingAlpha)
05:35AM	Lazard International Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-18-25 06:30AM	Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire) -6.94%
06:30AM	Loading…
Mar-11-25 06:30AM	Compass Pathways to Participate in Stifel Virtual CNS Forum (Business Wire)
Mar-05-25 11:06AM	Compass one of the most compelling stories in neuropsych, says H.C. Wainwright (TipRanks)
Mar-01-25 11:15AM	COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
02:11AM	Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ... (GuruFocus.com)
Feb-27-25 03:15PM	Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript (Motley Fool) +5.95%
06:30AM	Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-25-25 04:00PM	Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-18-25 06:30AM	Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 (Business Wire)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-05-25 06:30AM	Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +5.50%
Jan-21-25 06:30AM	Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer (Business Wire)
Jan-10-25 07:01AM	Compass Pathways Announces Pricing of Underwritten Offering (Business Wire) -14.73%
Dec-18-24 06:30AM	Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) (Business Wire) -6.43%
Nov-29-24 08:57PM	Is Your Mind Ready to Consider Investing in Psychedelics Stocks? (Motley Fool)
Nov-25-24 04:00PM	Compass Pathways to Participate in December Investor Conferences (Business Wire)
Nov-14-24 07:44AM	Compass Pathways to participate in Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-02-24 09:25AM	Compass Pathways cuts 30% of workforce on Phase 3 trial delays (TipRanks)
Nov-01-24 11:00AM	Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Oct-31-24 09:00PM	Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript (Motley Fool) -23.10%
08:03AM	Compass delays anticipated psilocybin readout, cuts staff (BioPharma Dive)
06:30AM	Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Oct-24-24 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 (Business Wire)
Sep-23-24 07:00AM	Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Aug-28-24 06:00AM	Compass Pathways to participate in three investor conferences in September (GlobeNewswire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-19-24 07:13AM	More promise for psilocybin in depression but safety remains a concern (Clinical Trials Arena)
Aug-12-24 12:47PM	FDA Rejection of MDMA Therapy Isnt End of Psychedelic-Drug Candidates (Barrons.com)
Aug-06-24 08:00AM	COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 11:30PM	Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript (Motley Fool) -9.83%
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-28-24 06:05PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-24-24 07:01AM	Compass Pathways to announce second quarter financial results on August 1, 2024 (GlobeNewswire)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +9.39%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 06:30AM	Compass Pathways appoints Lori Englebert as Chief Commercial Officer (GlobeNewswire)
Jun-24-24 04:01PM	Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-12-24 06:25AM	Should You Buy the Dip on Compass Pathways Stock? (Motley Fool) +7.04%
Jun-10-24 08:25AM	Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. (Motley Fool) -5.62%
Jun-09-24 06:14PM	After FDA setback, psychedelic drugmakers distance themselves from a pioneer (Washington Post)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal)
May-21-24 08:05AM	These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring (Motley Fool)
May-13-24 10:43AM	COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:45AM	Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript (Motley Fool)
May-08-24 06:45AM	Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
06:30AM	Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder (GlobeNewswire)
May-03-24 04:58PM	Compass Pathways to announce first quarter financial results on May 8, 2024 (GlobeNewswire)
May-02-24 06:30AM	Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment (GlobeNewswire)
Apr-29-24 06:30AM	Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (GlobeNewswire)
Apr-01-24 04:01PM	Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.35%
Mar-31-24 05:47PM	20 Most Depressed Countries in Asia (Insider Monkey)
Mar-28-24 08:00AM	Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors (GlobeNewswire) -12.42%
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-05-24 09:59AM	15 Highest Paying Jobs with a Psychology Degree (Insider Monkey) -5.48%
08:52AM	20 Countries with Most Antidepressant Users in the World (Insider Monkey)
Mar-01-24 09:08AM	COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.78%
Feb-29-24 03:30PM	Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript (Motley Fool) -16.98%
07:34AM	Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements (GuruFocus.com)
07:00AM	Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 12:33PM	Penny Power Players: 3 Stocks to Watch in the Microcap Arena (InvestorPlace) +9.64%
Feb-26-24 04:01PM	Compass Pathways to participate in upcoming TD Cowen investor conference (GlobeNewswire)
Feb-22-24 04:01PM	Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024 (GlobeNewswire)
Feb-21-24 03:06PM	Mental Health Mavericks: 3 Stocks Changing the Game (InvestorPlace)
Feb-19-24 07:00AM	Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. (Motley Fool)
Feb-02-24 04:27PM	As investors pile into psychedelics, idealism gives way to pharma economics (Associated Press Finance)
Jan-31-24 04:01PM	Compass Pathways to participate in upcoming Oppenheimer investor conference (GlobeNewswire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire) +7.87%

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATAI Life Sciences N.V.	10% Owner	Sep 26 '24	Sale	6.05	2,660,000	16,093,000	6,905,774	Sep 27 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Compass Pathways Plc ADR

Upgrade your FINVIZ experience